Effect of anti-VEGFR-3 treatment on tumor-associated mortality and tumor growth post–allo-HSCT in the BALB/c → C57BL/6 model. C57BL/6 allo-HSCT recipients received 1.5 × 107 BALB/c bone marrow cells and 5 × 105 EL4-TGL tumor cells. One milligram per mouse of control antibody or mF4-31c1 antibody was injected every second day from day 0 to day +16. (A) Schematic representation of the BALB/c → C57BL/6 GVHD model used for tumor experiments. (B-C) Allo-HSCT with bone marrow only; no T cells were given. (B) Survival curve of control antibody and mF4-31c1–treated allo-HSCT recipients (n = 4 per group). Data from one representative experiment are shown, analysis with the log-rank test. (C) Average radiance data of control antibody and mF4-31c1–treated allo-HSCT recipients (n = 4 per group). (D-E) Allo-HSCT with bone marrow and additional 3 × 105 donor splenic T cells. (D) Survival curve of control antibody and mF4-31c1–treated allo-HSCT recipients (n = 4 per group). Data from one representative experiment are shown, analysis with the log-rank test. (E) Average radiance data of control antibody and mF4-31c1– treated allo-HSCT recipients (n = 4 per group). Error bars indicate mean ± SEM; significance was tested with an unpaired Student t test.
